Antisense agents

Unknown Manufacturer

Generate AI report

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
- EP 4013767 A4
  Applicant: IONIS PHARMACEUTICALS INCPriority: 2019
  CN
  EP
  US
  WO
  9 publications
- US 20250154506 A1
  Applicant: IONIS PHARMACEUTICALS INCPriority: 2022
  US
- EP 4532724 A4
  Applicant: IONIS PHARMACEUTICALS INCPriority: 2022
  EP
Antisense oligonucleotides against cPLA2, compositions and uses thereof
US 8242255 B2Applicant: LEVY RACHELPriority: 2004
CN
EP
US
WO
8 publications
AChE antisense deoxyoligonucleotide as an anti-inflammatory agent
EP 2599489 A1Applicant: YISSUM RES DEV COPriority: 2003
EP
US
WO
7 publications
IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME
EP 4341403 A1Applicant: NOGRA PHARMA LTDPriority: 2021
CN
EP
US
WO
6 publications
AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
EP 3118316 A1Applicant: UNIVERSITÉ DE MONSPriority: 2010
EP
US
6 publications
DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES
US 2011263514 A1Applicant: SANFORD BURNHAM MED RES INSTPriority: 2010
US
WO
5 publications
ALPHA-V BETA-6 INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY
EP 4605008 A1Applicant: ALNYLAM PHARMACEUTICALS INCPriority: 2022
CN
EP
US
WO
4 publications
MTOR THERAPEUTICS FOR CANCER
EP 4661908 A1Applicant: GMP BIOTECHNOLOGY LTDPriority: 2023
CN
EP
US
WO
4 publications
ANTISENSE OLIGONUCLEOTIDE AGENTS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP3/NLRP1 EXPRESSION OR ACTIVATION
EP 4673547 A2Applicant: MOLECULAR AXIOM LLCPriority: 2023
CN
EP
US
WO
4 publications
Uses of DNA-PK
US 7700568 B2Applicant: SLOAN KETTERING INST CANCERPriority: 2000
US
4 publications

Drugs

Antisense agents

Patents

LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF